摘要
他莫昔芬在临床广泛用于雌激素受体阳性乳腺癌患者的治疗。该药可引起脂肪肝，主要危险因素为肥胖、高脂血症和高血糖。其发生机制包括药物拮抗雌激素、影响脂肪酸代谢酶的表达及活性、促进脂肪酸合成、影响脂质代谢相关核受体表达，多种因素干扰脂肪酸代谢，导致脂肪积聚于肝脏。奥贝胆酸能够改善他莫昔芬致脂肪肝患者的预后。
Tamoxifen is widely used in the treatment of patients with estrogen receptor positive breast cancer. Tamoxifen can lead to fatty liver. Risk factors of tamoxifen induced fatty liver were obesity, hyperlipidemia, and hyperglycemia. The mechanism of tamoxifen induced fatty liver includes drugs estrogen antagonism, influence on fatty acid metabolism enzyme expression and activity, promoting fatty acid synthesis, and influencing lipid metabolism related nuclear receptors. The above factors interfering with fatty acid metabolism cause fat accumulation in the liver. Obeticholic acid can improve the prognosis of patients with fatty liver induced by tamoxifen.
出处
《药物不良反应杂志》
CSCD
2016年第4期290-292,共3页
Adverse Drug Reactions Journal
